Does the dosage of sparsentan/sparsentan need to be adjusted according to the condition?

The dosage of Sparsentan/Sparsentan for the treatment of primary immunoglobulinA nephropathy needs to be individually adjusted according to the patient's specific condition, renal function status and tolerance. Treatment is usually started at a lower dose to reduce the risk of possible adverse reactions in the early stages, and is gradually adjusted to the recommended maintenance dose to ensure maximum efficacy.

In clinical practice, the initial dose of sparsentane is generally 200 mg orally once a day. After 14 days of continuous use, if the patient tolerates the drug well, the dose can be increased to 400 mg once a day as the recommended maintenance dose. This dosage adjustment plan is designed to gradually adapt to the drug, reduce the burden on liver and kidney function, and reduce the probability of side effects.

If the patient has interrupted treatment and resumes taking the drug again, it is usually recommended to increase the dosage from 200mg and follow the same dosage adjustment steps as for the first time to ensure safety. When taking the medicine, it is recommended that the patient swallow the tablet whole with water before breakfast and dinner, and maintain the stability of the medication time to avoid fluctuations in drug absorption that affect the efficacy.

Hepatotoxicity is an important concern during the use of sparsentane. If the patient develops clinical manifestations of hepatotoxicity, or the levels of liver enzymes and bilirubin in the blood do not return to baseline, the medication needs to be suspended until the indicators return to normal before evaluating whether to resume treatment. Patients with abnormal liver function should use it with caution and monitor liver function indicators regularly.

In addition, the metabolism of sparsentane is affected byCYP3A enzyme system. If patients need to take strong CYP3A inhibitors together, it may lead to a significant increase in drug concentration and increase the risk of adverse reactions. Therefore, it is recommended to suspend sparsentane treatment. Clinically, the dosage should be adjusted or drug interactions should be avoided in conjunction with the patient's overall medication regimen.

In short, dose adjustment is a key link to ensure the efficacy and safety of sparsentan. Professional doctors need to formulate a plan based on the patient's condition to ensure individualized treatment and achieve the best therapeutic effect.

Reference materials:https://www.sparsentan.com/